![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gulf Keystone Petroleum Ltd | LSE:GKP | London | Ordinary Share | BMG4209G2077 | COM SHS USD1.00 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.50 | -1.12% | 132.20 | 132.20 | 132.60 | 133.30 | 130.40 | 132.00 | 514,002 | 14:35:58 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Oil And Gas Field Expl Svcs | 123.51M | -11.5M | -0.0516 | -33.91 | 297.75M |
Date | Subject | Author | Discuss |
---|---|---|---|
10/1/2019 15:36 | "But I thought I was Oilwoman" See what I mean. Even you're confused. That's why it's better if we just call you Sarah. | ![]() habshan | |
10/1/2019 15:17 | But I thought I was Oilwoman lol | ![]() therectifier1 | |
10/1/2019 15:00 | OT) Please look at Futura Medical (FUM) has the BEST ERECTILE DYSFUNCTION DRUG out there wayy better than Viagra which is close to Phase 3 readout .Market cap is only 22 million Drug potential is 1+ BILLION =20++ BAGGER GEM .. Research Confirms MED2002's US$1 Billion Potential hxxps://futuramedica The latest market research further endorses Futura's strategy of developing MED2002 as a prescription product in standard and increased strength dose forms, with the objective of switching the standard dose form to an OTC product at an appropriate time. Ipsos's validated healthcare forecasting model was used to predict peak OTC annual sales for MED2002 in key countries worldwide in excess of US$650 million. This forecast follows earlier market research commissioned into the potential of MED2002 as a prescription product, which indicated a prescription market size of up to US$600 million in key countries worldwide. Ipsos forecasts that 70% of OTC product sales will be incremental to the prescription ED category. As a result, the estimated peak annual sales of MED2002 in prescription and OTC versions is predicted to be more than US$1 billion prior to the expiry of the product's expected patent life. The Ipsos valuation was based on the outcomes from primary market research carried out amongst 400 men with ED or suspected ED in the USA. The respondents were in four groups: satisfied users of PDE5 inhibitors (the class of drugs such as Viagra and Cialis); dissatisfied users of PDE5 inhibitors; diagnosed but untreated ED sufferers; and suspected though undiagnosed ED sufferers. The respondents were shown a concept about MED2002 as part of the market research though they did not use the product as it is currently in clinical development. The key findings of the market research showed that the respondents believed that the product, once approved, is highly differentiated from existing products and that its claims would meet their needs. MED2002's rapid onset of action, an average of less than five minutes, was the key feature that attracted respondents to the product and could command a price premium compared with existing ED treatments, which have a substantially slower onset of action. The Ipsos healthcare forecasting model has been demonstrated by Ipsos to be within 20% of actual sales volumes in 9 out of 10 of its forecasts. Pipeline hxxps://www.futurame MED2002 (topical treatment for erectile dysfunction) hxxps://futuramedica first patient dosed: in Q3/Q4 2018 Last patient dosed: by end of June 2019 Headline efficacy results: by end of December 2019 CSD500: Erectogenic condom hxxps://futuramedica Significant milestone achieved with approval of 2-year shelf life approved for CSD500, the erectogenic condom in September 2018. Development now complete. Discussions are ongoing with current and potential further distribution partners on next steps with the product in a number of markets. Pain relief products: TPR100 (diclofenac) and TIB200 (ibuprofen) hxxps://futuramedica TPR100 commercial partner Thornton & Ross filed for UK regulatory submission in July 2018. Out-licensing discussions for TPR100 outside of the UK are ongoing. | bioking | |
10/1/2019 14:54 | "You can call me Sarah or uncle Tony or what ever you want because it has zero effect and is totally irrelevant." "Sorry I forgot don't forget the Landrover parts lol." It's not intended to have an effect Sarah, it's simply to avoid any confusion amongst your multitude of avatars. And don't worry, we haven't forgotten the spare parts. In fact I always thought that SparePart would have been a far more appropriate avatar for you than Oilman. | ![]() habshan | |
10/1/2019 14:37 | Sorry I forgot don't forget the Landrover parts lol. | ![]() therectifier1 | |
10/1/2019 14:32 | Habscam You can call me Sarah or uncle Tony or what ever you want because it has zero effect and is totally irrelevant. Why don't you tell us about the pumps or your phone call to the Erbil office 😂😂 | ![]() therectifier1 | |
10/1/2019 14:10 | "I'm aware why you desperately need to try and identify me as a woman called Sarah " If you aren't a woman named Sarah then that would be absolutely amazing. Because we had a woman named Sarah on these boards who hasn't posted since the day that you began posting. She was a raving banshee who was obsessed with Robert Waterhouse just like you are, and like you posted about little else. You sound exactly like her. Amazing. | ![]() habshan | |
10/1/2019 14:07 | Why is habby talking to sarahGibbs like that? I thought they were mates:-). I do hope that's not another close relationship gone down the dunny, Lofl. How many nicknames has habby got through? Or Not out? Or the Guru? | ![]() bigdog5 | |
10/1/2019 13:58 | I'm aware why you desperately need to try and identify me as a woman called Sarah but unfortunately for you the people you are trying to convince in power can she right though your sad little blog game 😂😂 Absolutely NOBODY you have contacted is interested and why they don't sorry hate Bob. | ![]() therectifier1 | |
10/1/2019 13:46 | SP rocketing. First stop is 500p per share. You can take that to the bank. | ![]() gkphero | |
10/1/2019 12:49 | "It takes a few minutes and I have a new avatar and can just carry on on both here and the LSE." We all know that Sarah. And so can he. So why are you making a big deal out of HIS new avatar. Why do you think that his new avatar is worthy of mention. YOU'VE got through so many avatars over the years that they're meaningless. It's why it's a lot less confusing if we ignore them and just call you Sarah. You both have your unique styles. Yours posts are puerile nonsense. Whereas his are mature and considered. So it makes no difference what you call yourselves as we always know who's behind the posts. | ![]() habshan | |
10/1/2019 12:34 | Ps trev and Dave Roberts both believe greater Shaikan is bigger than Kirkuk though it will never see light of day | asherspoodles | |
10/1/2019 12:32 | But who cares what you think 😂😂 It takes a few minutes and I have a new avatar and can just carry on on both here and the LSE. You keep putting in the work and I'll carry on laughing at you 😂😂 | ![]() therectifier1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions